Neurocrine biosciences reports second quarter 2025 financial results

Achieved total net product sales of $682 million representing 17% year-over-year growth ingrezza® (valbenazine) second-quarter 2025 net product sales of $624 million and narrows 2025 net product sales guidance to $2.5 - $2.55 billion crenessity® (crinecerfont) second-quarter 2025 net product sales of $53 million with 664 total new patient enrollment start forms san diego , july 30, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its financial results for the second quarter ended june 30, 2025, and updated its 2025 financial guidance. "as we begin our transition into a new chapter of growth and diversification for neurocrine, we're pleased with our second quarter commercial performance across tardive dyskinesia, huntington's chorea, and now, classic congenital adrenal hyperplasia," said kyle w.
NBIX Ratings Summary
NBIX Quant Ranking